FeesSafety
Pluang+

Wabash reports Q3 2026 revenue up 25% but posts GAAP loss; backlog grows 25%, expects Q4 revenue $420-450M

Company Fundamentals
29 Oct 2026, 13:53 WIB
GlobeNewsWire
View Source
Neutral
Wabash reports Q3 2026 revenue up 25% but posts GAAP loss; backlog grows 25%, expects Q4 revenue $420-450M

Wabash National Corporation reported Q3 2026 revenue of $476 million, a 24.8% increase year-over-year, driven by strong shipments in the Dry Van market and growth in Parts & Services. Despite revenue growth, the company posted a GAAP operating loss of $20 million and a GAAP EPS of $(0.51), with a Non-GAAP adjusted operating loss of $27 million. The backlog rose 25% from the previous quarter to $1.198 billion, signaling strong customer demand. Wabash expects Q4 2026 revenue between $420 million and $450 million and a Non-GAAP EPS loss range of $(0.75) to $(0.55), with improvements anticipated thereafter.

Wabash's third quarter 2026 results show a 24.8% revenue increase to $476 million. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Oct 29, 2026 17:53 WIB: out of 135 priced stocks, 76 rose and 57 fell. Notable movers include Howmet Aerospace Inc (HWM) at USD 210.48 with a 7.76% gain and 100% buy order activity, FTAI Aviation Ltd (FTAI) at USD 180.00 up 7.69%, and Huntington Ingalls Industries Inc (HII) at USD 297.09 with a 6.38% rise.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App